De Novo device
Neba System
Lexicor Medical Technology, LLC · Neuropsychiatric Interpretative Electroencephalograph Assessment Aid (NCG, Class II) · First FDA decision Jul 15, 2013, newest Jul 15, 2013ADHD
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "Neba"
MAUDE reports
0
Brand "Neba", since 2015
PubMed studies
33
Mentioning "Neba"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Neba System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- NEBA SYSTEMNew device typeDe Novo
DEN110019 · Decided Jul 15, 2013 · 585 days after receipt
Device type: Neuropsychiatric Interpretative Electroencephalograph Assessment Aid (NCG) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Neba", any status and sponsor, newest update first.
No registered device study names "Neba".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Neba", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NCG
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Neba"[tiab]. The summary above synthesizes these.
- Seasonal ecology in ice-covered Arctic seas - Considerations for spill response decision making.
Aune M, Aniceto AS, Biuw M, et al. · Mar Environ Res · 2018Review
- Editorial Perspective: How should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor.
Arns M, Loo SK, Sterman MB, et al. · J Child Psychol Psychiatry · 2016Editorial
- Modifications in the carcinogen-metabolizing capacity of mouse liver treated with N-nitroso compounds.
Habib SL, Badawi AF, Aweny HA, et al. · Oncol Rep · 1998
- The bibliometric analysis and visualization mapping of net environmental benefit analysis (NEBA).
Buber M, Koseoglu B · Mar Pollut Bull · 2022
- Bioactivation of asymmetric N-dialkylnitrosamines in rat tissues derived from the ventral entoderm.
Ludeke B, Meier T, Kleihues P · IARC Sci Publ · 1991
- A framework for net environmental benefit analysis for remediation or restoration of contaminated sites.
Efroymson RA, Nicolette JP, Suter GW · Environ Manage · 2004Research Support, U.S. Gov't, Non-P.H.S.
- Species sensitivity assessment of five Atlantic scleractinian coral species to 1-methylnaphthalene.
Renegar DA, Turner NR · Sci Rep · 2021Research Support, Non-U.S. Gov't
- ADHD-A Clinician's Bird's Eye View of Current Status and New Vistas!
Naguy A, Pridmore S, Alwetayan S, et al. · Psychopharmacol Bull · 2023Review
- Commentary: Objective aids for the assessment of ADHD - further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016).
Stein MA, Snyder SM, Rugino TA, et al. · J Child Psychol Psychiatry · 2016Comment
- Novel study on N-nitrosamines as risk factors of cardiovascular diseases.
Sheweita SA, El-Bendery HA, Mostafa MH · Biomed Res Int · 2014Research Support, Non-U.S. Gov't
- Substitution of the U3 long terminal repeat region of the neurotropic Cas-Br-E retrovirus affects its disease-inducing potential.
Paquette Y, Kay DG, Rassart E, et al. · J Virol · 1990Research Support, Non-U.S. Gov't
- Counter-historical study of alternative dispersant use in the Deepwater Horizon oil spill response.
French-McCay DP, Robinson H, Bock M, et al. · Mar Pollut Bull · 2022
Other devices of this type
Also filed under product code NCG.
- Ceribell Delirium Monitor SystemCeribell, Inc. · 510(k) 2025
- DeltaScan MonitorProlira B.V. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.